臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

???ui.leftmenu.abouttair???
	???ui.leftmenu.explanation???

???ui.leftmenu.bartitle???
	Repositories
	Author
	Title
	Date
	???ui.leftmenu.statisticschart???
	???ui.leftmenu.realtimefacts???
	???ui.leftmenu.trend???

???index.news???
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

???ui.leftmenu.copyrighttitle???
	???ui.leftmenu.copyrightpublisher???
	???ui.leftmenu.copyrightconference???

???ui.leftmenu.link???
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"ou d l"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1???	???jsp.browse.items-by-author.order2???

Showing items 31-55 of 103 (5 Page(s) Totally)
<< < 1 2 3 4 5 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2021-09-01T01:54:19Z	Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma	Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:54:12Z	Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells	Ou D.-L.; Shen Y.-C.; Yu S.-L.; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:54:08Z	IκB kinases increase Myc protein stability and enhance progression of breast cancer cells	Yeh P.-Y.; Lu Y.-S.; Ou D.-L.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:55Z	KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells	Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:51Z	Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma	Shen Y.-C.; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:48Z	Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway	Ou D.-L.; Lee B.-S.; Chang Y.-C.; Lin L.-I.; Liou J.-Y.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:25Z	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma	Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:24Z	Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin	Ou D.-L.; Lee B.-S.; Lin L.-I.; Liou J.-Y.; Liao S.-C.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:18Z	Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma	Ou D.-L.; Shyue S.-K.; Lin L.-I.; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:43Z	Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression	Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; ANN-LII CHENG; Ou D.-L.
臺大學術典藏	2021-08-31T06:29:34Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C.
臺大學術典藏	2021-08-31T06:29:32Z	Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy	Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG; Hsu C.
臺大學術典藏	2021-08-31T06:29:25Z	Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma	Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; ANN-LII CHENG; Hsu C.
臺大學術典藏	2021-08-11T03:46:42Z	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma	Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:38Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏	2021-05-02T03:56:41Z	Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer	Ou D.-L.; Tseng S.-J.; Kempson I.M.; Hsu C.-L.; PAN-CHYR YANG; Liao Z.-X.
臺大學術典藏	2021-03-15T07:59:42Z	MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine	Lu J.-W.;Lin Y.-M.;Lai Y.-L.;Chen C.-Y.;Chung-Yi Hu;Tien H.-F.;Ou D.-L.;Lin L.-I.; Lu J.-W.; Lin Y.-M.; Lai Y.-L.; Chen C.-Y.; CHUNG-YI HU; Tien H.-F.; Ou D.-L.; Lin L.-I.
臺大學術典藏	2021-03-15T07:59:41Z	Cytarabine-resistant FLT3-ITD leukemia cells are associated with TP53 mutation and multiple pathway alterations—possible therapeutic efficacy of cabozantinib	Ko Y.-C.;Chung-Yi Hu;Liu Z.-H.;Tien H.-F.;Ou D.-L.;Chien H.-F.;Lin L.-I.; Ko Y.-C.; CHUNG-YI HU; Liu Z.-H.; Tien H.-F.; Ou D.-L.; Chien H.-F.; Lin L.-I.
臺大學術典藏	2021-03-15T07:59:41Z	Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)	Lu J.-W.;Wang A.-N.;Liao H.-A.;Chen C.-Y.;Hou H.-A.;Chung-Yi Hu;Tien H.-F.;Ou D.-L.;Lin L.-I.; Lu J.-W.; Wang A.-N.; Liao H.-A.; Chen C.-Y.; Hou H.-A.; CHUNG-YI HU; Tien H.-F.; Ou D.-L.; Lin L.-I.
臺大學術典藏	2021-03-09T05:18:38Z	Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma	Ou D.-L.; Ying-Chun Shen; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:35Z	Induction of DNA damage-inducible gene GADD45�] contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells	Ou D.-L.; Ying-Chun Shen; Yu S.-L.; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:32Z	Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma	Ying-Chun Shen; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; Cheng A.-L.
臺大學術典藏	2021-02-18T08:01:17Z	Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma	Ou D.-L.; Shen Y.-C.; JA-DER LIANG; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-02-05T06:29:41Z	CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia	Lin T.-C.;Hou H.-A.;Wen-Chien Chou;Ou D.-L.;Yu S.-L.;Tien H.-F.;Lin L.-I.; Lin T.-C.; Hou H.-A.; WEN-CHIEN CHOU; Ou D.-L.; Yu S.-L.; Tien H.-F.; Lin L.-I.
臺大學術典藏	2021-02-02T02:47:55Z	Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma	Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; PING-NING HSU; Cheng A.-L.; Hsu C.

Showing items 31-55 of 103 (5 Page(s) Totally)
<< < 1 2 3 4 5 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| 0
	???header.visitor??? : 50716719 ???header.onlineuser??? : 405 ???header.sponsordeclaration???